Additionally, immunotherapy approaches such as immune checkpoint inhibitors targeting the programmed cell death protein 1 and its ligand (PD-1/PD-L1) pathways are being explored in poorly differentiated subtypes like SCLC and LCNEC, although their efficacy remains variable and requires further investigation [41,42,43]. Here, PDCD1 is linked to large cell neuroendocrine carcinoma.